De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation [J]. Eur Urol, 2011, 60(1):106-117.
[2]
Liu L, Li Q, Han P, et al. Evaluation of interleukin-8 in expressed prostatic secretion as a reliable biomarker of inflammation in benign prostatic hyperplasia [J]. Urology, 2009, 74(2):340-344.
[3]
Ding HS, Yang J, Gong FL, et al. High mobility group [corrected] box 1 mediates neutrophil recruitment in myocardial ischemia-reperfusion injury through toll like receptor 4-related pathway [J]. Gene, 2012, 509(1):149-153.
[4]
Degryse B, Bonaldi T, Scaffidi P, et al. The high mobility group(HMG)boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells [J]. J Cell Biol, 2001, 152(6):1197-1206.
[5]
AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia(2003). Chapter 1: Diagnosis and treatment recommendations [J]. J Urol, 2003, 170(2 Pt 1):530-547.
[6]
Wang H, Bloom O, Zhang M, et al. HMG-1 as a late mediator of endotoxin lethality in mice [J]. Science, 1999, 285(5425):248-251.
[7]
Kokkola R, Sundberg E, Ulfgren AK, et al. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis [J]. Arthritis and rheumatism, 2002, 46(10):2598-2603.
[8]
Nickel JC, Roehrborn CG, O'Leary MP, et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the reduce trial [J]. Eur Urol, 2008, 54(6):1379-1384.
[9]
Tang D, Kang R, Livesey KM, et al. Endogenous HMGB1 regulates autophagy [J]. J Cell Biol, 2010, 190(5):881-892.
